retatrutide clinical trial results is getting a lot of attention in the weight loss space. It's natural to feel curious when new medications enter the conversation around obesity and metabolic health. Medications can be helpful VisualAbstract: Retatrutide reduces body weight

Prescribers who authorize compounded combinations without appropriate clinical justification may face increased scrutiny or liability under federal and state law 2

Finally, since Wegovy mimics the GLP-1 hormone, it may influence bodily fluid and potentially impact tear production

La inyeccin subcutnea de Mounjaro (tirzepatida 5 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg y 12.5 mg), solo con receta mdica, no ha sido aprobada por la FDA como segura ni eficaz para tratar la obesidad o el sobrepeso

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Most patients reach their maximum tolerated dose by week 16

They have issued more than 50 warning letters to companies manufacturing or selling fraudulent compounded semaglutide and tirzepatide products